Health Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer's disease, raising questions about its effectiveness and availability in Canada. Lecanemab is a lab-made antibody given by intravenous infusion. It targets the buildup of amyloid plaque in the
